Vanda AI Stock Analysis
Want to see VNDA full AI Analyst Report?
Vanda (VNDA) AI Stock Analysis
Vanda
(NASDAQ:VNDA)
VNDA scores below average primarily due to deteriorating profitability and accelerating cash burn, which outweigh a balance-sheet leverage cushion. Technicals also detract as the stock trades below major moving averages with bearish momentum, though oversold indicators hint pressure may be extended. The latest earnings call provides some support via stronger revenue trends, upcoming launches, and expense reductions, but near-term funding/runway risk remains elevated given the cash decline and higher expected cash burn.
Vanda (VNDA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $230.39M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.05M
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 0.58
- Revenue Growth
- 8.11%
- EPS Growth
- -222.50%
- Country
- US
- Employees
- 533
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Vanda Business Overview & Revenue Model
Company Description
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-2...
How the Company Makes Money
Vanda makes money primarily by selling prescription pharmaceuticals. Its revenue is generated from (1) product sales of its marketed drugs—HETLIOZ, Fanapt, and PONVORY—through distribution to wholesalers/specialty pharmacies and ultimately to healthc...
Vanda Earnings Call Summary
The call was broadly positive, supported by 24% third-quarter revenue growth, strong Fanapt prescription trends, positive NEREUS and HETLIOZ clinical results, the expected BYSANTI launch, the Quimilza regulatory milestone, and declining quarterly operating expenses. These positives were partly offset by a larger year-to-date net loss, a substantial cash balance decline, expected higher 2026 cash burn, continued generic pressure on HETLIOZ, constrained early NEREUS revenue, and ongoing regulatory proceedings.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Vanda updated its full year 2026 total revenue guidance, expecting total revenues from Fanapt, BYSANTI, HETLIOZ, PONVORY, and NEREUS of greater than $240 million; NEREUS revenue is likely to be less than $10 million for the full year of 2026, while NEREUS total prescriptions and unique prescribers in Q3 2026 increased by over 100% versus Q2 2026. Vanda is not providing 2026 cash guidance at this time, but it is likely that Vanda's 2026 cash burn will be greater than the cash burn in 2025. Operating expenses decreased by 18% to $93.3 million from $114.3 million in Q2 of 2026 and are expected to decrease further in future quarterly periods. BYSANTI is expected to launch in the fourth quarter of 2026, Quimilza could be ready with commercial product a few months after December, with the goal of being on the market in the first half of 2027, and the BYSANTI MDD study is expected to complete in the first half of 2027.
Vanda Financial Statement Overview
Summary
Despite modest TTM revenue growth (+6.3%) and a low-leverage balance sheet (TTM debt-to-equity ~0.09), fundamentals are pressured by sharply worsened profitability (very large operating losses; net margin ~-120%) and decisively negative cash generation (deeply negative TTM operating cash flow and free cash flow with further contraction).
Income Statement
28NegativeBalance Sheet
74PositiveCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 229.28M | 216.10M | 198.77M | 192.64M | 254.38M | 268.68M |
| Gross Profit | 212.59M | 203.06M | 187.46M | 177.84M | 230.10M | 243.05M |
| EBITDA | -162.09M | -126.73M | -14.79M | 9.35M | 14.03M | 45.20M |
| Net Income | -274.83M | -220.47M | -18.90M | 2.51M | 6.28M | 33.15M |
Balance Sheet | ||||||
| Total Assets | 382.33M | 488.95M | 656.20M | 648.44M | 634.25M | 593.79M |
| Cash, Cash Equivalents and Short-Term Investments | 140.49M | 263.85M | 374.64M | 388.26M | 466.86M | 432.81M |
| Total Debt | 21.97M | 12.62M | 12.36M | 9.40M | 11.14M | 12.37M |
| Total Liabilities | 182.47M | 161.76M | 117.66M | 103.53M | 107.05M | 88.86M |
| Stockholders Equity | 199.86M | 327.19M | 538.55M | 544.91M | 527.20M | 504.93M |
Cash Flow | ||||||
| Free Cash Flow | -190.40M | -110.44M | -16.25M | 12.42M | 31.30M | 63.66M |
| Operating Cash Flow | -189.36M | -109.44M | -15.76M | 12.80M | 31.98M | 64.21M |
| Investing Cash Flow | 154.35M | 94.86M | -17.43M | -12.06M | 49.92M | -76.70M |
| Financing Cash Flow | -3.92M | -2.91M | -155.00K | 0 | 734.00K | 3.55M |
Vanda Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VNDA, the sentiment is Negative. The current price of 3.81 is below the 20-day moving average (MA) of 3.93, below the 50-day MA of 4.43, and below the 200-day MA of 5.98, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 40.60 is Neutral, neither overbought nor oversold. The STOCH value of 48.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VNDA.
Vanda Risk Analysis
Vanda disclosed 60 risk factors in its most recent earnings report. Vanda reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksVanda Peers Comparison
Overall Rating
VNDA49Neutral
NRXP47Neutral
AVXL46Neutral
NERV41Neutral
NMRA40Underperform
MPLT39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $230.39M | -0.83 | -106.94% | ― | 8.11% | -222.50% | |
| 47Neutral | $108.60M | -4.53 | 247.77% | ― | 1681.40% | 77.82% | |
| 46Neutral | $68.60M | -4.97 | -11.43% | ― | ― | 73.28% | |
| 41Neutral | $107.64M | -0.08 | 167.68% | ― | ― | -1306.84% | |
| 40Underperform | $63.12M | -0.29 | -320.56% | ― | ― | 27.16% | |
| 39Underperform | $365.13M | -1.20 | -61.01% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VNDA | Vanda Pharmaceuticals | 3.81 | -1.33 | -25.88% | |
| NERV | Minerva Neurosciences | 2.16 | -2.14 | -49.77% | |
| AVXL | Anavex Life Sciences | 0.74 | -2.86 | -79.44% | |
| NRXP | Nrx Pharmaceuticals, Inc. | 2.45 | 0.32 | 15.02% | |
| NMRA | Neumora Therapeutics, Inc. | 0.33 | -2.21 | -86.85% | |
| MPLT | MapLight Therapeutics, Inc. | 6.57 | -8.03 | -55.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026
